Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Altaf Saadi, Meha Prabhu, Sara A Snyder, Lynn Daboul, Farrah J Mateen
There are more than 100 million forcibly displaced persons (FDPs) in the world today, including a high number of people who experience neurologic symptoms and presentations. This review summarizes the conceptual frameworks for understanding neurological health risks and conditions across the migration journey (premigration, migration journey, and postmigration) and life span, including special attention to pediatric FDPs. The interaction with psychiatric illness is discussed, as well as the available published data on neurologic presentations in FDPs in the medical literature...
March 18, 2024: Seminars in Neurology
#2
Methma Udawatta, Farrah J Mateen
Nicolau syndrome is a rare, iatrogenic skin reaction after parental drug administration, characterized by severe pain at an injection site, followed by hemorrhage, ulceration, and often necrosis. We present a case of a patient on glatiramer acetate for many years (initially Copaxone then Glatopa) who developed Nicolau syndrome, the second reported case after generic glatiramer acetate. All reported cases of Nicolau syndrome after glatiramer acetate are reviewed. The case highlights the importance of prompt recognition of this skin reaction by neurologists and raises awareness of the risks of skin reactions even in low-risk injectable DMTs...
March 14, 2024: Annals of Clinical and Translational Neurology
#3
JOURNAL ARTICLE
Isabella Gomez Hjerthen, Cristina Trápaga Hacker, William Meador, Ahmed Z Obeidat, Lucas Horta, Farrah J Mateen
BACKGROUND AND OBJECTIVES: We aim to characterize the sociodemographic and clinical factors associated with loss of jobs, income, and work hours in people with neuromyelitis optica spectrum disorder (NMOSD) in the United States. METHODS: A REDCap-based survey was administered to working-age NMOSD patients (18-70 years old) querying demographic information, symptoms, immunosuppression, work hours, income, and caregiver work (11/2022-07/2023). Regression models were developed using MATLAB...
February 20, 2024: Annals of Clinical and Translational Neurology
#4
JOURNAL ARTICLE
Kristin Galetta, Andrew Siyoon Ham, Anastasia Vishnevetsky, Shamik Bhattacharyya, Farrah J Mateen
Tumefactive multiple sclerosis (TMS) is characterized by large demyelinating brain lesions. This was a retrospective cohort study of 67 patients with TMS between January 2015-2023, examining different disease modifying therapy impact on expanded disability scale score change at follow-up. Median age was 36 with a female predominance. Mean EDSS was 3.3 ± 2.3 at TMS onset, 2.1 ± 1.9 at year one, and 2.1 ± 1.9 at last follow-up. A multilinear regression model found higher presentation EDSS and post-diagnosis non-B-cell high efficacy therapies were each independently associated with higher EDSS at last follow up...
March 15, 2024: Journal of Neuroimmunology
#5
JOURNAL ARTICLE
Farren B S Briggs, Erika S Trapl, Farrah J Mateen, Alessandro De Nadai, Devon S Conway, Douglas D Gunzler
BACKGROUND: We previously reported more rapid accrual of ambulatory impairments in Black compared to White individuals with relapsing remitting multiple sclerosis (RRMS) and higher body mass index (BMI). Hypertension and lower neighborhood socioeconomic status (SES) were associated with greater impairment, irrespective of race. We hypothesize that these common social and health inequities may explain a substantial portion of the racial differences in ambulation in American individuals with RRMS...
2024: International Journal of MS Care
#6
JOURNAL ARTICLE
Shawheen J Rezaei, Fodé Abass Cissé, Mohamed Lamine Touré, Rui Duan, Dylan R Rice, Andrew Siyoon Ham, Damien de Walque, Farrah J Mateen
OBJECTIVE: Most people with epilepsy (PWE) could live seizure free if treated with one or more antiseizure medications (ASMs). The World Health Organization (WHO) estimates that 75% of PWE in low-resource settings lack adequate antiseizure treatment. Limited education surrounding epilepsy and the out-of-pocket costs of ASMs in particular pose barriers to managing epilepsy in resource-poor, low-income settings. The aim of this study is to implement and test a novel strategy to improve outcomes across the epilepsy care cascade marked by (1) retention in epilepsy care; (2) adherence to ASMs; and (3) seizure reduction, with the measured goal of seizure freedom...
December 22, 2023: Epilepsia Open
#7
JOURNAL ARTICLE
Dylan R Rice, Carlos Othon Guelngar, Mohamed Traoré, Mohamed Laminé Condé, Djenabou Diallo, Nathanael J Lee, Andrew Siyoon Ham, Fodé Abass Cissé, Farrah J Mateen
BACKGROUND AND OBJECTIVE: Of ~5 million people living with epilepsy (PLWE) in Sub-Saharan Africa, roughly one-third experience depression and over one third experience anxiety. In Guinea, these issues may be compounded by fewer available resources, such as appropriate anti-seizure medications (ASMs). We aim to quantify seizure frequency, anxiety and depression in PLWE in Guinea, before and after a free ASM intervention and neurologist's consultation. METHODS: Guinean participants >12 years old with ≥2 unprovoked seizure were prospectively recruited...
November 29, 2023: Tropical Medicine & International Health
#8
JOURNAL ARTICLE
Farrah J Mateen, Cristina Trápaga Hacker
OBJECTIVE: To explore the social determinants of health (SDOH) in people with multiple sclerosis (MS) with SDOH, elucidating the SDOH variables of highest salience in this geographical region. METHODS: Focus groups and a structured survey of Massachusetts residents with SDOH and a diagnosis of MS were conducted by a neurologist and staff, December 2022-July 2023, via Zoom™. Twenty-one consecutively-recruited, convenience-sampled adults participated in four groups...
October 19, 2023: Multiple Sclerosis and related Disorders
#9
JOURNAL ARTICLE
Andrew Siyoon Ham, Mohamed Traore, Guelngar Carlos Othon, Mohamed Lamine Conde, Toure Mohamed Lamine, Barry Souleymane Djigué, Condé Kaba, Diawara Karinka, Doumbouya Idrissa, Camara Idrissa, Djenabou Diallo, Rui Duan, Dylan R Rice, Fode Abass Cisse, Farrah J Mateen
BACKGROUND: This study assesses perceptions of quality of life (QOL) and overall health in people with epilepsy (PWE) in Guinea after a clinical intervention providing modified and new antiseizure medicine (ASM) regimens. METHODS: Participants 12 years and older diagnosed with active epilepsy were prospectively and consecutively enrolled at two health centers in the Republic of Guinea (one urban, one rural) in 2022. 95% of participants were prescribed new/increased ASM doses, and interviewed for QOL and overall health perceptions at enrollment and three- and six-month follow ups...
July 17, 2023: Seizure: the Journal of the British Epilepsy Association
#10
JOURNAL ARTICLE
Domenico Plantone, Eleonora Sabatelli, Sara Locci, Mariano Marrodan, Sini M Laakso, Farrah J Mateen, Amalia Feresiadou, Tom Buelens, Assunta Bianco, Marcela P Fiol, Jorge Correale, Pentti Tienari, Paolo Calabresi, Nicola De Stefano, Raffaele Iorio
BACKGROUND AND PURPOSE: Serum levels of neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are promising neuro-axonal damage and astrocytic activation biomarkers. Susac syndrome (SS) is an increasingly recognized neurological condition and biomarkers that can help assess and monitor disease evolution are highly needed for the adequate management of these patients. sNfL and sGFAP levels were evaluated in patients with SS and their clinical relevance in the relapse and remission phase of the disease was assessed...
June 19, 2023: European Journal of Neurology
#11
JOURNAL ARTICLE
Farrah J Mateen
The standard of care for patients with neuromyelitis optica (NMO) has become highly unequal globally. Sufficient data have been published to demonstrate that NMO is a disabling-and at times, fatal-disease needing preventive immunosuppressive treatment. Since 2019, there are multiple regulatory authority-approved disease-modifying therapies (DMTs) for aquaporin-4 antibody seropositive NMO for patients. Reframing the picture of NMO globally is now needed. When considered as a disease of high mortality when left untreated, parallel programs to those for cancer, HIV/AIDS, or tuberculosis can be considered...
June 10, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#12
JOURNAL ARTICLE
Giovanna S Manzano, Dylan R Rice, Jonathan Zurawski, Youmna Jalkh, Rohit Bakshi, Farrah J Mateen
BACKGROUND: Familial Mediterranean Fever (FMF) is associated with increased risk of multiple sclerosis (MS). Optimal treatment of patients with comorbid FMF and MS remains uncertain. CASE: A 28-year-old woman with FMF, treated with colchicine, had symptomatic onset of relapsing remitting MS following four simultaneous vaccines. MRI brain with a 7-Tesla magnet demonstrated several areas of leptomeningeal enhancement with predominant linear, spread/fill and rare nodular patterns...
June 15, 2023: Journal of Neuroimmunology
#13
JOURNAL ARTICLE
Nicoline Schiess, Violet Kulo, Pria Anand, David R Bearden, Aaron L Berkowitz, Gretchen L Birbeck, Anna Cervantes-Arslanian, Phillip Chan, Lorraine Chishimba Chishimba, Felicia C Chow, Isabel Elicer, Agnes Fleury, Aarti Kinikar, Michelle Kvalsund, Farrah J Mateen, Amir A Mbonde, Ana-Claire L Meyer, Cumara B O'Carroll, Adesola Ogunniyi, Archana A Patel, Michael Rubenstein, Omar K Siddiqi, Serena Spudich, Sean A Tackett, Kiran T Thakur, Nirali Vora, Joseph Zunt, Deanna R Saylor
OBJECTIVE: Use a modified Delphi approach to develop competencies for neurologists completing <u>></u>1 year of advanced global neurology training. METHODS: An expert panel of 19 US-based neurologists involved in global health was recruited from the American Academy of Neurology Global Health Section and the American Neurological Association International Outreach Committee. An extensive list of global health competencies was generated from review of global health curricula and adapted for global neurology training...
March 30, 2023: Neurology
#14
JOURNAL ARTICLE
Farrah J Mateen, Cristina M Trápaga Hacker
Neuromyelitis optica spectrum disorder (NMOSD) is a rare and disabling neurological disorder, marked by recurrent attacks of the central nervous system. NMO has a high female predominance and disproportionately affects racial and ethnic groups who are under- and unemployed in the USA. Three focus groups, involving 20 working age adults with NMOSD in the USA, were convened via Zoom online, to discuss the topic of employment in NMOSD. Consolidated Criteria for Reporting Qualitative research (COREQ) were followed...
2023: Frontiers in Neurology
#15
JOURNAL ARTICLE
Robert P McInnis, Muhammad Abubakar Ayub, Jin Jing, Jonathan J Halford, Farrah J Mateen, M Brandon Westover
OBJECTIVE: To construct a tool for non-experts to calculate the probability of epilepsy based on easily obtained clinical information combined with an artificial intelligence readout of the electroencephalogram (AI-EEG). MATERIALS AND METHODS: We performed a chart review of 205 consecutive patients aged 18 years or older who underwent routine EEG. We created a point system to calculate the pre-EEG probability of epilepsy in a pilot study cohort. We also computed a post-test probability based on AI-EEG results...
March 3, 2023: Epilepsy & Behavior: E&B
#16
JOURNAL ARTICLE
Farrah J Mateen, Ibrahem Hanafi, Gretchen L Birbeck, Altaf Saadi, Erich Schmutzhard, Jo M Wilmshurst, MRCPaed FCPaed, Amy Bennett, Lyell K Jones
There is a growing number of forcibly displaced persons (FDPs) worldwide. With more than 100 million people forcibly displaced today, there is an urgent mandate to understand the neurologic care needs of this population and how neurologists and other health care workers can most effectively provide that care. In this Emerging Issues in Neurology article, we attempt to: (1) define the scope of the problem of providing neurologic care to FDPs, (2) highlight commonly encountered clinical challenges related to neurologic care of FDPs, and (3) provide useful clinical information for neurologists and other clinicians who deliver care to FDPs with neurologic needs...
March 1, 2023: Neurology
#17
JOURNAL ARTICLE
Dylan R Rice, Kathryn B Holroyd, Danielle Kei Pua, Michael Levy, Farrah J Mateen, Shamik Bhattacharyya
We surveyed 103 adults (mean age 46 years; 85% female) with neuromyelitis optica spectrum disorders (NMOSD) through social media about their personal economic burden of NMOSD emergency department visits and hospitalizations ("relapse events"). The average number of relapse events over the prior 3 years was 5.3. Participants reported direct, out-of-pocket costs for 52% of events (mean cost per event 3326 USD, 95% CI [2378,4274]) and indirect costs (e.g., childcare) for 26% (mean cost per event 1907 USD, 95% CI [1159,2655])...
February 15, 2023: Multiple Sclerosis and related Disorders
#18
REVIEW
Ruth Dobson, Dylan R Rice, Marie D'hooghe, Rachel Horne, Yvonne Learmonth, Farrah J Mateen, Claudia H Marck, Saúl Reyes, Mitzi Joi Williams, Gavin Giovannoni, Helen L Ford
Social determinants of health are the conditions in which people are born, grow, live, work and age. These circumstances are the non-medical factors that influence health outcomes. Evidence indicates that health behaviours, comorbidities and disease-modifying therapies all contribute to multiple sclerosis (MS) outcomes; however, our knowledge of the effects of social determinants - that is, the 'risks of risks' - on health has not yet changed our approach to MS. Assessing and addressing social determinants of health could fundamentally improve health and health care in MS; this approach has already been successful in improving outcomes in other chronic diseases...
December 2022: Nature Reviews. Neurology
#19
JOURNAL ARTICLE
Sjors G J G In 't Veld, Mohammad Arkani, Edward Post, Mafalda Antunes-Ferreira, Silvia D'Ambrosi, Daan C L Vessies, Lisa Vermunt, Adrienne Vancura, Mirte Muller, Anna-Larissa N Niemeijer, Jihane Tannous, Laura L Meijer, Tessa Y S Le Large, Giulia Mantini, Niels E Wondergem, Kimberley M Heinhuis, Sandra van Wilpe, A Josien Smits, Esther E E Drees, Eva Roos, Cyra E Leurs, Lee-Ann Tjon Kon Fat, Ewoud J van der Lelij, Govert Dwarshuis, Maarten J Kamphuis, Lisanne E Visser, Romee Harting, Annemijn Gregory, Markus W Schweiger, Laurine E Wedekind, Jip Ramaker, Kenn Zwaan, Heleen Verschueren, Idris Bahce, Adrianus J de Langen, Egbert F Smit, Michel M van den Heuvel, Koen J Hartemink, Marijke J E Kuijpers, Mirjam G A Oude Egbrink, Arjan W Griffioen, Rafael Rossel, T Jeroen N Hiltermann, Elizabeth Lee-Lewandrowski, Kent B Lewandrowski, Philip C De Witt Hamer, Mathilde Kouwenhoven, Jaap C Reijneveld, William P J Leenders, Ann Hoeben, Irma M Verdonck-de Leeuw, C René Leemans, Robert J Baatenburg de Jong, Chris H J Terhaard, Robert P Takes, Johannes A Langendijk, Saskia C de Jager, Adriaan O Kraaijeveld, Gerard Pasterkamp, Minke Smits, Jack A Schalken, Sylwia Łapińska-Szumczyk, Anna Łojkowska, Anna J Żaczek, Henk Lokhorst, Niels W C J van de Donk, Inger Nijhof, Henk-Jan Prins, Josée M Zijlstra, Sander Idema, Johannes C Baayen, Charlotte E Teunissen, Joep Killestein, Marc G Besselink, Lindsay Brammen, Thomas Bachleitner-Hofmann, Farrah Mateen, John T M Plukker, Michal Heger, Quirijn de Mast, Ton Lisman, D Michiel Pegtel, Harm-Jan Bogaard, Jacek Jassem, Anna Supernat, Niven Mehra, Winald Gerritsen, Cornelis D de Kroon, Christianne A R Lok, Jurgen M J Piek, Neeltje Steeghs, Winan J van Houdt, Ruud H Brakenhoff, Gabe S Sonke, Henk M Verheul, Elisa Giovannetti, Geert Kazemier, Siamack Sabrkhany, Ed Schuuring, Erik A Sistermans, Rob Wolthuis, Hanne Meijers-Heijboer, Josephine Dorsman, Cees Oudejans, Bauke Ylstra, Bart A Westerman, Daan van den Broek, Danijela Koppers-Lalic, Pieter Wesseling, R Jonas A Nilsson, W Peter Vandertop, David P Noske, Bakhos A Tannous, Nik Sol, Myron G Best, Thomas Wurdinger
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors...
August 30, 2022: Cancer Cell
#20
JOURNAL ARTICLE
Giovanna S Manzano, Rebecca Salky, Farrah J Mateen, Eric C Klawiter, Tanuja Chitnis, Michael Levy, Marcelo Matiello
Myelin oligodendrocyte glycoprotein antibody associated disease (MOG-AD) is a CNS demyelinating disease, typically presenting with optic neuritis, transverse myelitis, and/or ADEM-like syndromes. The positive predictive value (PPV) of MOG-IgG testing by live cell-based assay was reported to be 72% in a study performed at the Mayo Clinic using a cut-off of 1:20. PPV may vary depending upon the tested population, thus supporting further investigation of MOG-IgG testing at other centers. In this real-world institutional cohort study, we determined the PPV of serum MOG-IgG for clinically defined MOG-AD in our patient population...
2022: Frontiers in Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
